21:24:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Combigene är ett forskningsbolag. Idag fokuserar bolaget på att utveckla nya behandlingar avsedda för olika neurologiska sjukdomar. Störst fokus ligger inom behandling utav epilepsi, men även behandling av övriga nervsjukdomar förekommer. Idag innehas samarbete mellan Lunds Universitet och Köpenhamns Universitet, som ligger till grund för forskningsarbetet. Combigene har huvudkontor i Lund.

Kalender

2020-11-13 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-06-30 Ordinarie utdelning COMBI 0.00 SEK
2020-06-29 Årsstämma 2019
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-17 Kvartalsrapport 2019-Q1
2019-05-16 Årsstämma 2018
2019-05-15 Ordinarie utdelning COMBI 0.00 SEK
2019-02-14 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-04 Ordinarie utdelning COMBI 0.00 SEK
2018-05-03 Årsstämma 2017
2018-05-03 Kvartalsrapport 2018-Q1
2018-01-29 Bokslutskommuniké 2017
2017-11-01 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-18 Kvartalsrapport 2017-Q1
2017-05-10 Ordinarie utdelning COMBI 0.00 SEK
2017-05-09 Årsstämma 2016
2017-01-31 Bokslutskommuniké 2016
2017-01-26 Extra Bolagsstämma 2017
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-19 Kvartalsrapport 2016-Q1
2016-04-05 Ordinarie utdelning COMBI 0.00 SEK
2016-04-04 Årsstämma 2015
2016-02-18 Bokslutskommuniké 2015
2015-11-19 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2020-06-29 17:15:00

Today, on 29 June 2020, CombiGene AB held its annual general meeting (“AGM”) in Lund. The AGM elected Filip Funk, lawyer at Fredersen Advokatbyrå, as the chairman of the meeting and keeper of the minutes. The AGM resolved on all matters in accordance with previously published proposed resolutions by the board of directors or the nomination committee. A summary of the most important resolutions adopted follows below.

Dividend
In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2019.

Election of the board of directors, auditor and resolutions on remuneration
Bert Junno, Jan Nilsson, Jonas Ekblom and Per Lundin were elected as new members of the board. Peter Nilsson was re-elected as a board member. Bert Junno was elected as the new chairman of the board of directors. It was resolved that remuneration will amount to SEK 200,000 to the chairman of the board and SEK 125,000 to every other board member who do not receive any salary from the company.

MAZARS SET Revisionsbyrå AB was re-elected as the company’s auditor, with Anders O Persson as the principal auditor. The AGM resolved on remuneration according to approved invoices.

Discharge from liability
The AGM resolved to discharge the board of directors and the CEO from liability for the financial year 2019.

Resolution regarding amendment to the Articles of Association
The AGM resolved to amend the Articles of Association according to the table below.

Previous wordingResolved wording
1 § Registered name
The company’s registered name is CombiGene AB. The company is public (“publ”).

1 § Business name
The company’s business name is CombiGene AB. The company is public (“publ”).
3 § The object of the company's business
The object of the company's business is to develop and commercialize gene therapy for treatment of primarily neurological and psychiatric diseases as well as any other business compatible therewith.
3 § The object of the company's business
The object of the company's business is to develop and commercialize gene therapy for treatment of
serious diseases that today lack adequate treatment methods as well as any other business compatible therewith.
4 § Share capital
The share capital shall be not less than SEK 5,000,000 and not more than SEK 20,000,000.

4 § Share capital
The share capital shall be not less than SEK 10,000,000 and not more than SEK 40,000,000.

5 § Number of shares
The number of shares in the company shall be not less than 50,000,000 and not more than 200,000,000.
5 § Number of shares
The number of shares in the company shall be not less than 100,000,000 and not more than 400,000,000.

Authorisation for the board of directors to resolve on new issues 0f shares, convertibles or warrants
The AGM resolved, in accordance with the proposed resolution in the notice to the AGM, to authorize the board of directors to, on one or more occasions before the next AGM, with or without pre-emption rights for the shareholders, resolve on new issues of shares as well as issues of warrants and/or convertibles.

Lund, 29 June 2020

CombiGene AB

The board of directors